@ARTICLE{Cecha_Patrycja_Assessment_2021,
 author={Cecha, Patrycja and Chromik, Anna and Piotrowska, Ilona and Zabojszcz, Michał and Dolecka-Ślusarczyk, Magdalena and Siudak, Zbigniew},
 volume={Vol. 61},
 number={No 3},
 journal={Folia Medica Cracoviensia},
 pages={43-54},
 howpublished={online},
 year={2021},
 publisher={Oddział PAN w Krakowie; Uniwersytet Jagielloński – Collegium Medicum},
 abstract={Background: Cardiovascular diseases are the first cause of death globally. Hypercholester-olemia is the most important factor responsible for atherosclerotic plaque formation and increasing cardiovascular risk. Reduction of LDL-C level is the most relevant goal for reduction of cardiovascular risk. Aims: Real life adherence to guidelines concerning statin therapy in one center study population. Methods: We analyzed data collected in the Department of Internal Diseases from September 2019 to February 2020, obtained from 238 patients hospitalized in this time period. We assessed application of the new 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias in daily clinical practice and compared effectiveness of LLT according to 2016 and 2019 guidelines. Results: Only 1 in 5 patients with dyslipideamia achieve the 2019 ESC/EAS guideline-recommended levels of LDL-C with relation to their TCVR. We noticed that 20 of patients who did not achieve proper 2019 LDL level, meet the therapy targets established in year 2016. We observed that higher patient TCVR resulted in better compliance with guidelines and ordination of proper LLT. Most patients were on monotherapy with statins. Conclusions: It could be beneficial to start treatment with double or even triple therapy especially in group with the highest LDL-C levels.},
 type={Article},
 title={Assessment of application of the new 2019 European Society of Cardiology/ European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias in daily clinical practice — one center study},
 URL={http://www.czasopisma.pan.pl/Content/122083/PDF/2021-03-FMC-04-Cecha.pdf},
 doi={10.24425/fmc.2021.138950},
 keywords={cardiovascular risk, ESC/EAS guidelines, lipid-lowering therapy, PCSK9 inhibitors, statins},
}